This augmented approach was first tested in randomized fashion by the Children's Cancer Group, finding that ALL patients with a slow early response to induction therapy (>25% blasts in bone marrow at day 7 of induction) had superior event free survival when treated with augmented post-induction chemotherapy with added asparaginase doses compared to those treated with the standard, non-augmented chemotherapy backbone (96). The gene discussed is ASPG; the disease is cancer.